Troika operates with a focus on pharmaceutical quality and structured access to solutions aligned with the demands of contemporary clinical practice.
GLP-1 therapy is an innovative metabolic approach that acts on hormonal receptors involved in glycemic control and appetite regulation, contributing to improved metabolic outcomes and body weight reduction in patients with type 2 diabetes and obesity.
Administration is performed subcutaneously, typically with weekly application, which supports therapeutic adherence and structured clinical follow-up.
It may be considered for patients with type 2 diabetes, obesity, and metabolic disorders, always subject to individualized medical evaluation.
Clinical response may vary according to the patient’s metabolic profile, treatment adherence, and medical follow-up. Progressive benefits are typically observed throughout the course of therapy.
Yes. Indication, monitoring, and therapeutic adjustments must always be performed by a licensed healthcare professional.
Troika Medical develops injectable solutions with rigorous technical control, full traceability, and pharmaceutical standardization, providing structured support to healthcare professionals working with modern metabolic therapies.
Our commitment is to expand access to treatments aligned with the evolution of clinical practice, with safety and reliability at every stage.
Troika provides structured B2B distribution with full product traceability, technical documentation, and dedicated support for licensed clinics and medical professionals.
All products are manufactured under strict quality control protocols at our partner laboratory in the United States, ensuring consistent concentration, purity, and compliance with pharmaceutical manufacturing standards.
Access is exclusive to licensed healthcare professionals. Interested clinics and physicians can get in touch directly through our website or contact channels to learn about partnership and supply conditions.
© 2026 Troika Medical Group. All rights reserved.